drugset

drugset / Trial / NCT02588937

Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients

NCT02588937 ↗

Phase 4 Unknown 76 enrolled Chong Kun Dang Pharmaceutical

RandomizedOpen-labelTreatment

Summary

The purpose of this study is to evaluate the antiviral activity and safety of EntecaBell ODT. in chronic hepatitis B Patients.

Timeline

Start: 2015-10
Primary completion: 2017-02
Completion: 2017-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	EntecaBell ODT. 0.5mg	Unknown	0.5 mg	—

Indications